Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.41 |
| ▸ | IL6 | P05231 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129651 | 0.97 | TLR7 (0.41) | TLR7IL6ADORA2AADORA2B | |
| SCHEMBL4148559 | 0.87 | TLR7 (0.41) | TLR7IL6ADORA2AADORA2B | |
| SCHEMBL4133491 | 0.85 | TLR7 (0.40) | TLR7IL6ADORA2AADORA2B | |
| SCHEMBL4135343 | 0.83 | TLR7 (0.53) | TLR7IL6 | |
| SCHEMBL13849545 | 0.80 | TLR7 (0.52) | TLR7IL6 | |
| SCHEMBL4134349 | 0.79 | TLR7 (0.54) | TLR7IL6 | |
| SCHEMBL14153739 | 0.75 | TLR7 (0.53) | TLR7IL6 | |
| SCHEMBL4135725 | 0.74 | TLR7 (0.50) | TLR7IL6ADORA2AADORA2B | |
| SCHEMBL4129551 | 0.74 | TLR7 (0.52) | TLR7IL6 | |
| SCHEMBL4127024 | 0.72 | TLR7 (0.49) | TLR7IL6ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | TLR7 389/4885IL6 3503/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.